Vectorious’ V-LAP System Evaluated in Early Data From VECTOR HF Trials

July 8, 2024—Vectorious Medical Technologies Ltd. announced the publication of a pilot clinical study that evaluated the Vectorious left atrial pressure (V-LAP) system. V-LAP is a miniature digital pressure sensor and a novel therapeutic approach for heart failure (HF).

The interim insights from the VECTOR-HF I and IIa studies of physician-directed patient self-management in HF using V-LAP were published by David Meerkin, MBBS, et al in the European Journal of Heart Failure.

According to the company, V-LAP enables HF patients to better control their disease by monitoring the heart’s LAP and detecting fluid accumulation in the earliest stages of the disease, before physiological symptoms. A mobile app allows patients to self-titrate medication in real-time based on data extracted from the heart.

Vectorious stated that the V-LAP device is implanted in the heart’s interatrial septum via a catheterization procedure. The sensor transmits data that allows physician-directed, patient self-management of chronic HF. Through the dedicated mobile application and based on daily data transmitted from the left atrium, patients self-adjust their diuretic dosage with the aim of preventing disease deterioration and repeated hospitalizations.

As summarized in the company’s press release, the study demonstrated for that self-management of HF based on LAP is both safe and feasible. No complications or side effects related to the system were reported at 12 months of follow-up. Additionally, patient adherence to treatment was high, and significant improvements were observed in quality-of-life measures, coupled with a reduction in hospitalizations because of heart failure.

“This groundbreaking study marks a significant milestone in heart failure management by placing control directly in the hands of patients,” commented Dr. Meerkin in the company’s press release. “This approach, akin to the empowerment seen in diabetes management, enables heart failure patients, under the guidance of their heart failure management team, to monitor and manage their condition safely with ease and confidence. By fostering greater patient autonomy, this innovative shift is set to dramatically enhance care quality and outcomes for this vulnerable population.”

The company noted that to date, 55 V-LAP sensors have been implanted in patients across Europe and Israel, accumulating more than 40,000 days of LAP monitoring. In the next phase of expansion of the Vectorious clinical trials, implantations are planned to begin this summer in leading heart centers in the United States.

William T. Abraham, MD, Professor of Medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio, added, “This study marks another significant step in realizing the transformative potential of patient self-management guided by LAP monitoring. By empowering patients with real-time hemodynamic data and decision-making tools, this innovative approach may not only enhance patient-centered outcomes but also shift the paradigm towards proactive and personalized HF care.”